论文部分内容阅读
本文介绍了白屈菜Chelidonrum majus L.生物碱的制剂Ukrain对癌症患者免疫激活作用的临床试验的初步结果。共有27名不同癌症患者用Ukrain治疗,其中男性11名,女性16名,年龄23～76岁(平均年龄52.5岁),包括肺癌1O人,乳腺癌7人,皮肤和软组织癌5人,卵巢癌3人,胸膜间皮瘤1人,何杰金氏病1人。除1名肺癌病人外,全部肺癌患者在接受Ukrain治疗后进行常规化疗,其余18人中,13人接受手术治疗后再放疗(9人)、化疗(1人)或单纯手术治疗结合Ukrain治疗(3
This paper presents the preliminary results of a clinical trial of celandin Chelidonrum majus L. alkaloid formulation Ukrain on immune activation in cancer patients. A total of 27 different cancer patients were treated with Ukrain, including 11 males and 16 females, aged 23 to 76 years (mean age 52.5 years), including 1O lung cancer, 7 breast cancers, 5 skin and soft tissue cancers, and ovarian cancer Three were pleural mesothelioma and one was Hodgkin’s disease. Except for one patient with lung cancer, all patients with lung cancer received conventional chemotherapy after receiving Ukrain therapy. Of the remaining 18 patients, 13 received surgery followed by radiation (9), chemotherapy (1), or surgery alone combined with Ukrain ( 3